Gastrointestinal Stromal Tumors (GISTs) Treatment Market

The global Gastrointestinal Stromal Tumors (GISTs) Treatment market was valued at USD 1.60 billion in 2025 and is estimated at USD 1.73 billion in 2026. The market is projected to reach USD 3.20 billion by 2034, exhibiting an endpoint-consistent 8.0% CAGR during 2026–2034.

Gastrointestinal stromal tumors are rare mesenchymal tumors of the gastrointestinal tract that arise most often from interstitial cells of Cajal or related precursor cells. Molecular alterations in KIT and PDGFRA drive most adult GISTs and transformed treatment from primarily surgical management into a model of mutation-directed kinase inhibition. NCI estimates more than 6,000 new GIST cases each year in the United States, with diagnosis concentrated in older adults and disease arising most often in the stomach and small intestine.

Treatment depends on resectability, recurrence risk, tumor genotype and prior therapy. Surgery remains the principal curative approach for localized resectable disease. For unresectable, metastatic or recurrent KIT/PDGFRA-variant GIST, imatinib is standard first-line therapy for most patients. Patients with PDGFRA D842V-mutant disease are treated with avapritinib because this mutation is highly resistant to imatinib, while sunitinib, regorafenib and ripretinib are established subsequent-line options after progression or intolerance.

The commercial market is therefore dominated by oral tyrosine kinase inhibitors rather than conventional cytotoxic chemotherapy. Generic imatinib broadens first-line access, while mutation-specific and later-line branded agents support higher per-patient value. Current ownership has also evolved: Sanofi completed its acquisition of Blueprint Medicines in July 2025, gaining Ayvakit/avapritinib, while Ono Pharmaceutical acquired Deciphera in June 2024, adding QINLOCK/ripretinib and its ongoing GIST development program.

The study covers treatment of adult and selected rare pediatric GIST, including surgery and systemic anticancer therapy across localized, adjuvant, unresectable, metastatic and recurrent settings.

Targeted therapy has created long-duration systemic treatment demand

GIST is one of the clearest examples of oncogene-driven therapy. Imatinib can control advanced KIT/PDGFRA-sensitive disease for prolonged periods, converting a rare tumor into a chronic treatment market for many patients and creating sequential demand as resistance develops.

Molecular testing directly determines treatment selection

NCI emphasizes mutational analysis before or during treatment planning because KIT exon 9, PDGFRA D842V, SDH deficiency and other subtypes differ materially in kinase-inhibitor sensitivity. Wider next-generation sequencing therefore increases appropriate use of mutation-specific drugs.

Generic imatinib improves first-line affordability

Imatinib is now available from multiple generic manufacturers. This lowers first-line drug cost and improves access but shifts value growth toward later-line and mutation-specific therapies such as avapritinib and ripretinib.

Acquired resistance creates a structured treatment sequence

Secondary KIT mutations frequently emerge under kinase-inhibitor pressure. Patients may move from imatinib to sunitinib, regorafenib and ripretinib or into genotype-directed trials, creating a multi-line commercial pathway.

Rare-disease incidence limits absolute patient volume

GIST is the most common mesenchymal GI tumor but still represents less than 1% of gastrointestinal tumors. Market value therefore depends heavily on treatment duration and specialty-drug pricing rather than very large patient counts.

Second-line molecular selection could reshape the treatment sequence

The Phase 3 INSIGHT study evaluates ripretinib versus sunitinib in patients progressing on imatinib who harbor co-occurring KIT exon 11 and 17/18 mutations. A positive outcome could move ripretinib earlier in a genomically selected population.

PDGFRA D842V has validated mutation-specific drug development

NCI reports an 88% overall response rate with avapritinib in the NAVIGATOR PDGFRA D842V cohort. This success supports development strategies focused on difficult resistance mutations rather than broad undifferentiated kinase inhibition.

Generic first-line therapy increases the accessible treated population

Current 2026 DailyMed listings include multiple ANDA-authorized imatinib products with GIST indications. Lower acquisition cost can improve access in emerging markets and public oncology programs.

Adjuvant therapy sustains treatment beyond metastatic disease

Imatinib is used after complete resection in patients with sufficiently high recurrence risk. NCI and current labeling support prolonged adjuvant treatment in selected high-risk patients, expanding market demand into earlier disease.

Asia-Pacific offers growing diagnosis and treatment opportunity

NCI notes comparatively high recorded GIST incidence in several Asian populations. Expanding molecular pathology and access to generic imatinib, sunitinib and later-line therapies support regional growth.

Treatment is organized by resectability, recurrence risk, mutation profile and prior kinase inhibitor exposure.

Targeted Therapy leads market value because conventional chemotherapy and radiotherapy have limited effectiveness in most GIST, while surgery is concentrated in resectable disease.

Hospitals are the largest care setting because diagnosis, surgery, multidisciplinary review and management of complex metastatic disease are concentrated in tertiary oncology centers.

Imatinib remains the largest treated-patient segment, while newer drugs carry higher per-patient value in resistant or mutation-specific disease.

Unresectable / Metastatic disease accounts for the largest systemic-treatment value because patients may remain on sequential oral TKIs for prolonged periods.

Molecular subtype is the most important predictor of systemic-treatment sensitivity and increasingly determines commercial drug selection.

North America

North America is the largest market. The United States has more than 6,000 newly diagnosed GIST cases annually, advanced molecular testing and broad access to imatinib, sunitinib, regorafenib, avapritinib and ripretinib. High specialty-drug pricing and rapid uptake of mutation-directed treatment support value leadership.

Europe

Europe has mature sarcoma-center networks and broad access to sequential TKIs. Germany, France, Italy, Spain and the United Kingdom are major national markets. Ongoing health-technology assessment and generic imatinib use moderate first-line cost while preserving later-line specialty-drug value.

Asia-Pacific

Asia-Pacific is the fastest-growing region. NCI notes relatively high reported GIST incidence in China, Taiwan and Korea, while Japan has long-standing access to targeted therapies. China and India are expanding pathology, molecular testing and generic TKI access.

Latin America

Brazil and Mexico lead regional treatment demand. Access to generic imatinib is broader than access to mutation-specific or later-line branded drugs, creating a significant treatment-sequencing gap and a future market-access opportunity.

Middle East & Africa

GCC oncology centers increasingly offer advanced molecular testing and targeted therapy, while broader African access is constrained by rare-tumor diagnostic capacity and specialty-drug affordability. Regional referral centers are the primary high-value treatment sites.

GIST treatment is highly dependent on molecular diagnosis and the approved line of therapy for each kinase inhibitor.

The market is concentrated around a small set of branded TKIs layered on top of broad generic imatinib competition.

• Novartis
• Pfizer
• Bayer
• Sanofi / Blueprint Medicines
• Ono Pharmaceutical / Deciphera Pharmaceuticals
• Sun Pharmaceutical
• Natco Pharma
• Teva Pharmaceutical Industries
• Viatris
• Dr. Reddy's Laboratories
• F. Hoffmann-La Roche
• AB Science
• Mendus (formerly Immunicum)

The global Gastrointestinal Stromal Tumors (GISTs) Treatment market is projected to grow from USD 1.73 billion in 2026 to USD 3.20 billion by 2034, at an 8.0% CAGR. Growth will be driven by molecular testing, longer targeted-therapy duration, mutation-specific drugs, sequential treatment and broader access in Asia-Pacific.

The study supports oncology portfolio strategy, rare-tumor market access, mutation-specific drug planning, clinical sequencing and competitive benchmarking.